文献速递白血病

白三烯促进急性髓系白血病干细胞自我更新与化疗耐药

Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2022-04-23

急性髓系白血病(AML)标准诱导化疗后复发率高、临床结局差,其化疗耐药的分子机制尚不清楚。本研究鉴定出ALOX5是蒽环类化疗耐药的新介导因子:ALOX5在AML患者原始细胞中转录上调,诱导治疗后mRNA和蛋白表达增加;体外和体内遗传及药物扰动实验证实ALOX5正向调控AML白血病干细胞的致白血病潜能,且其缺失对正常造血干/祖细胞功能无显著影响。ALOX5通过白三烯合成能力(特别是调控LTB4合成及其与BLTR结合)介导对柔红霉素的耐药并促进AML细胞存活与维持。

要点

  • ALOX5在AML患者原始细胞中较正常造血干/祖细胞转录上调,诱导治疗后mRNA和蛋白表达增加。
  • ALOX5正向调控AML白血病干细胞的致白血病潜能,其缺失对正常造血干/祖细胞功能无显著影响。
  • ALOX5通过LTB4合成及与BLTR结合介导柔红霉素耐药并促进AML细胞存活。

核心结论

  • ALOX5是蒽环类化疗耐药的新介导因子,通过LTB4合成及与BLTR结合促进AML细胞存活和白血病干细胞功能。
  • 抑制ALOX5介导的LTB4合成与功能可与标准化疗联合以提高AML整体疗效(作者结论)。

研究设计与样本

  • 研究通过鉴定AML诱导治疗耐药基因,阐明ALOX5作为蒽环类化疗耐药新介导因子。
  • 采用体外和体内遗传及药物扰动研究验证ALOX5功能。

主要发现

  • ALOX5在AML患者原始细胞中较正常造血干/祖细胞转录上调,诱导治疗后mRNA和蛋白表达增加。
  • ALOX5正向调控AML白血病干细胞的致白血病潜能,其缺失对正常造血干/祖细胞功能无显著影响。
  • ALOX5通过白三烯合成能力(特别是调控LTB4合成及其与BLTR结合)介导对柔红霉素的耐药并促进AML细胞存活与维持。

临床怎么用

  • 作者认为抑制ALOX5介导的LTB4合成与功能可与标准化疗联合,以提高AML整体疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is characterized by poor clinical outcomes due to high rates of relapse following standard-of-care induction chemotherapy. While many pathogenic drivers have been described in AML, our understanding of the molecular mechanisms mediating chemotherapy resistance remains poor. Therefore, we sought to identify resistance genes to induction therapy in AML and elucidated ALOX5 as a novel mediator of resistance to anthracycline-based therapy. ALOX5 is transcriptionally upregulated in AML patient blasts in comparison to normal hematopoietic stem/progenitor cells (HSPCs) and ALOX5 mRNA, and protein expression is increased in response to induction therapy. In vitro, and in vivo genetic, and pharmacologic perturbation studies confirm that ALOX5 positively regulates the leukemogenic potential of AML LSCs, and its loss does not significantly affect the function of normal HSPCs. ALOX5 mediates resistance to daunorubicin (DNR) and promotes AML cell survival and maintenance through its leukotriene (LT) synthetic capacity, specifically via modulating the synthesis of LTB4 and its binding to LTB receptor (BLTR). Our study reveals a previously unrecognized role of LTs in AML pathogenesis and chemoresistance, whereby inhibition of ALOX5 mediated LTB4 synthesis and function could be combined with standard chemotherapy, to enhance the overall therapeutic efficacy in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stranahan AW, Berezniuk I, Chakraborty S, et al. Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia. Leukemia. 2022. PMID: 35461365. doi:10.1038/s41375-022-01579-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。